Results 141 to 150 of about 39,918 (251)

Apixaban plasma concentrations before and after catheter ablation for atrial fibrillation.

PLoS ONE
BackgroundCatheter ablation in patients with atrial fibrillation is associated with a transient increase in thromboembolic risk and adequate anticoagulation is highly important.
Rachel Aakerøy, Jan Pål Loennechen, Roar Dyrkorn, Stian Lydersen, Arne Helland, Olav Spigset   +5 more
doaj   +1 more source

Clozapine‐Associated Pulmonary Embolism: Continuation of Clozapine Therapy With Concurrent Anticoagulation

Case Reports in Psychiatry, Volume 2026, Issue 1, 2026.
Clozapine, a gold standard for treatment‐resistant schizophrenia, is associated with a range of adverse effects, including the rare but serious risk of pulmonary embolism (PE). The management of such complications, particularly in the absence of clear guidelines for preventive anticoagulation, poses significant challenges.
M. R. Jahangir, C. Heerema, J. Biedermann, S. Dieleman, N. H. Grootendorst-van Mil, Philipp Sand   +5 more
wiley   +1 more source

Cost-effectiveness of Apixaban versus Warfarin and Aspirin in Sweden for Stroke Prevention in Patients with Atrial Fibrillation [PDF]

, 2014
Tereza Lanitis, Thitima Kongnakorn, Lena Jacobson, Anna De Geer   +3 more
openalex   +1 more source

Dependence of clot structure and fibrinolysis on apixaban and clotting activator

Research and Practice in Thrombosis and Haemostasis
Background: Anticoagulants prevent the formation of potentially fatal blood clots. Apixaban is a direct oral anticoagulant that inhibits factor (F)Xa, thereby impeding the conversion of prothrombin into thrombin and the formation of blood clots.
Rebecca A. Risman, Mitali Shroff, Julie Goswami, Valerie Tutwiler   +3 more
doaj   +1 more source

Effects of apixaban compared with warfarin as gain in event-free time – a novel assessment of the results of the ARISTOTLE trial [PDF]

, 2019
Erik Berglund, Lars Wallentin, Jonas Oldgren, Henrik Renlund, John H. Alexander, Christopher B. Granger, Stefan H. Hohnloser, Elaine M. Hylek, Renato D. Lópes, John J.V. McMurray, Per Lytsy   +10 more
openalex   +1 more source

Secondary stroke prevention with apixaban in nonvalvular atrial fibrillation: A subgroup analysis of the STANDARD study [PDF]

, 2020
Masahiro Yasaka, Michiaki Umeyama, Hirohide Kataoka, Hiroshi Inoue   +3 more
openalex   +1 more source

Associations of Apixaban Dose With Safety and Effectiveness Outcomes in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease [PDF]

, 2023
Yunwen Xu, Alex R. Chang, Lesley A. Inker, Mara McAdams‐DeMarco, Morgan E. Grams, Jung‐Im Shin   +5 more
openalex   +1 more source

Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches? [PDF]

, 2014
Al-Khatib, SM, Banerjee, A, Blendea, D, Camm, AJ, Conroy, JM, Cosio, FG, De Bono, J, G Cosio, MD, Guasch, E, Halperin, JL, Hess, PL, Kirchhof, P, Lip, GY, Nattel, S, Ruskin, J, Savelieva, I   +15 more
core   +1 more source

Comparing the Efficacy and Safety of Different DOACs (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) for Stroke Prevention in Atrial Fibrillation [PDF]

Dinesh Balamurugan, Collins Gilbert, Michael A�mann, Harsh Bansal   +3 more
openalex   +1 more source

Apixaban has been available for the treatment of venous thromboembolic disease for more than two years [PDF]

, 2017
Debora Karetová, Jan Bultas
openalex   +1 more source